Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Intangibles: 2018-2025

Historic Intangibles for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $11,808.

  • China SXT Pharmaceuticals' Intangibles fell 38.18% to $11,808 in Q1 2025 from the same period last year, while for Mar 2025 it was $11,808, marking a year-over-year decrease of 38.18%. This contributed to the annual value of $11,808 for FY2025, which is 38.18% down from last year.
  • According to the latest figures from FY2025, China SXT Pharmaceuticals' Intangibles is $11,808, which was down 38.18% from $19,101 recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Intangibles registered a high of $85,728 during FY2022, and its lowest value of $11,808 during FY2025.
  • Moreover, its 3-year median value for Intangibles was $19,101 (2024), whereas its average is $19,592.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Intangibles rose by 8.08% in 2021 and then crashed by 67.49% in 2023.
  • Over the past 5 years, China SXT Pharmaceuticals' Intangibles (Yearly) stood at $82,948 in 2021, then increased by 3.35% to $85,728 in 2022, then crashed by 67.49% to $27,868 in 2023, then slumped by 31.46% to $19,101 in 2024, then slumped by 38.18% to $11,808 in 2025.